These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 31633396)
1. Advances of proteomics technologies for multidrug-resistant mechanisms. Zhang T; Yuan Q; Gu Z; Xue C Future Med Chem; 2019 Oct; 11(19):2573-2593. PubMed ID: 31633396 [TBL] [Abstract][Full Text] [Related]
2. The use of proteomic technologies to study molecular mechanisms of multidrug resistance in cancer. Cao Y; Li Z; Mao L; Cao H; Kong J; Yu B; Yu C; Liao W Eur J Med Chem; 2019 Jan; 162():423-434. PubMed ID: 30453249 [TBL] [Abstract][Full Text] [Related]
3. Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Zhang JT; Liu Y Cancer Treat Rev; 2007 Dec; 33(8):741-56. PubMed ID: 17854999 [TBL] [Abstract][Full Text] [Related]
4. Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer. Li XH; Li C; Xiao ZQ J Proteomics; 2011 Nov; 74(12):2642-9. PubMed ID: 21964283 [TBL] [Abstract][Full Text] [Related]
5. MRP1-dependent Collateral Sensitivity of Multidrug-resistant Cancer Cells: Identifying Selective Modulators Inducing Cellular Glutathione Depletion. Lorendeau D; Dury L; Nasr R; Boumendjel A; Teodori E; Gutschow M; Falson P; Di Pietro A; Baubichon-Cortay H Curr Med Chem; 2017; 24(12):1186-1213. PubMed ID: 27855620 [TBL] [Abstract][Full Text] [Related]
6. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies. Li W; Zhang H; Assaraf YG; Zhao K; Xu X; Xie J; Yang DH; Chen ZS Drug Resist Updat; 2016 Jul; 27():14-29. PubMed ID: 27449595 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of multidrug resistance in cancer. Gillet JP; Gottesman MM Methods Mol Biol; 2010; 596():47-76. PubMed ID: 19949920 [TBL] [Abstract][Full Text] [Related]
8. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function. Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385 [TBL] [Abstract][Full Text] [Related]
9. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976 [TBL] [Abstract][Full Text] [Related]
10. Advances in the proteomic discovery of novel therapeutic targets in cancer. Guo S; Zou J; Wang G Drug Des Devel Ther; 2013; 7():1259-71. PubMed ID: 24187485 [TBL] [Abstract][Full Text] [Related]
11. Cytotoxic and multidrug resistance reversal activities of novel 1,4-dihydropyridines against human cancer cells. Shekari F; Sadeghpour H; Javidnia K; Saso L; Nazari F; Firuzi O; Miri R Eur J Pharmacol; 2015 Jan; 746():233-44. PubMed ID: 25445037 [TBL] [Abstract][Full Text] [Related]
12. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes. To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522 [TBL] [Abstract][Full Text] [Related]
13. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Vadlapatla RK; Vadlapudi AD; Pal D; Mitra AK Curr Pharm Des; 2013; 19(40):7126-40. PubMed ID: 23829373 [TBL] [Abstract][Full Text] [Related]
14. Modulating ROS to overcome multidrug resistance in cancer. Cui Q; Wang JQ; Assaraf YG; Ren L; Gupta P; Wei L; Ashby CR; Yang DH; Chen ZS Drug Resist Updat; 2018 Nov; 41():1-25. PubMed ID: 30471641 [TBL] [Abstract][Full Text] [Related]
15. Cancer Treatment by Using Traditional Chinese Medicine: Probing Active Compounds in Anti-multidrug Resistance During Drug Therapy. Lou JS; Yao P; Tsim KWK Curr Med Chem; 2018; 25(38):5128-5141. PubMed ID: 28933300 [TBL] [Abstract][Full Text] [Related]
16. The multi-factorial nature of clinical multidrug resistance in cancer. Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396 [TBL] [Abstract][Full Text] [Related]
17. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies. Tolomeo M; Simoni D Curr Med Chem Anticancer Agents; 2002 May; 2(3):387-401. PubMed ID: 12678739 [TBL] [Abstract][Full Text] [Related]
18. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells. Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359 [TBL] [Abstract][Full Text] [Related]
19. Different strategies to overcome multidrug resistance in cancer. Saraswathy M; Gong S Biotechnol Adv; 2013 Dec; 31(8):1397-407. PubMed ID: 23800690 [TBL] [Abstract][Full Text] [Related]
20. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles. Zhang Q; Li F Curr Pharm Des; 2013; 19(37):6655-66. PubMed ID: 23621532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]